Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Eli Lilly (NY: LLY)
112.53 USD  +2.01 (+1.82%)
Official Closing Price  /  Updated: 6:30 PM EDT, Aug 19, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,903,500
Open 111.05
Bid (Size) 110.60 (1)
Ask (Size) 114.80 (4)
Prev. Close 110.52
Today's Range 110.79 - 112.94
52wk Range 103.66 - 132.13
Shares Outstanding 1,085,430,420
Dividend Yield 2.00%
Performance
YTD
-2.05%
-2.05%
1 Month
+4.90%
+4.90%
3 Month
-3.18%
-3.18%
6 Month
-7.86%
-7.86%
1 Year
+6.34%
+6.34%
Top News
More News
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20th meeting of the International Association for... Read More
from PR Newswire
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at... Read More
from PR Newswire
More News
Read More
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with
from PR Newswire
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
from PR Newswire
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
from PR Newswire
UPDATE 1-Roche taps Lilly executive Garraway as chief medical officer
category companyNews
from Reuters: Company News
Roche taps Eli Lilly executive as chief medical officer
category companyNews
from Reuters: Company News
UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
category companyNews
from Reuters: Company News
UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr
category companyNews
from Reuters: Company News
UPDATE 1-FDA approves AbbVie's new rheumatoid arthritis drug
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.